WallStSmart

Centene Corp (CNC)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Centene Corp generates 1368% more annual revenue ($176.15B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs -3.8%. CNC appears more attractively valued with a PEG of 0.74. VRTX earns a higher WallStSmart Score of 66/100 (B-).

CNC

Strong Buy

65

out of 100

Grade: B-

Growth: 8.0Profit: 2.5Value: 6.7Quality: 5.8
Piotroski: 4/9Altman Z: 2.71

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CNC.

VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNC4 strengths · Avg: 8.5/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.748/10

Growing faster than its price suggests

Revenue GrowthGrowth
23.2%8/10

Revenue surging 23.2% year-over-year

EPS GrowthGrowth
21.8%8/10

Earnings expanding 21.8% YoY

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

CNC3 concerns · Avg: 1.3/10
Return on EquityProfitability
-28.7%2/10

ROE of -28.7% — below average capital efficiency

Profit MarginProfitability
-3.8%1/10

Currently unprofitable

Operating MarginProfitability
-1.9%1/10

Operating margin of -1.9%

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CNC

The strongest argument for CNC centers on Price/Book, PEG Ratio, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum. PEG of 0.74 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : CNC

The primary concerns for CNC are Return on Equity, Profit Margin, Operating Margin.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CNC profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

CNC carries more volatility with a beta of 0.46 — expect wider price swings.

CNC is growing revenue faster at 23.2% — sustainability is the question.

VRTX generates stronger free cash flow (349M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 65/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Centene Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Centene Corporation is a large publicly traded company and a multi-line managed care enterprise that serves as a major intermediary for both government-sponsored and privately insured health care programs. It is a healthcare insurer that focuses on managed care for uninsured, underinsured, and low-income individuals.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?